CEO Nicholas Saccomano was paid $1,467,934 in fiscal year 2025, ↓ down 84.6% from fiscal year 2024 (SEC filing 0001140361-26-015903 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$1,467,934 ↓ Nicholas Saccomano total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
You have just read OnKure Therapeutics, Inc.'s Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper OKUR reports.
We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
OKUR's next annual pay disclosure, estimated April 26, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Nicholas Saccomano | $600,000 | $0 | $0 | $609,934 | $247,500 | $0 | $10,500 | $1,467,934 |
| President and Chief Executive Officer | ||||||||
| Jason Leverone | 444,000 | 0 | 0 | 304,967 | 133,200 | 0 | 14,000 | 896,167 |
| Chief Financial Officer | ||||||||
| Samuel Agresta | 482,000 | 0 | 0 | 211,131 | 144,600 | 0 | 14,000 | 851,731 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Nicholas Saccomano | $1,467,934 | $9,515,165 | — | ↓ −8,047,231 |
| Jason Leverone | 896,167 | 2,678,570 | — | ↓ −1,782,403 |
| Samuel Agresta | 851,731 | 2,841,068 | — | ↓ −1,989,337 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
How we handle your data → Privacy
This is the complete answer, not a partial one — the list is never padded.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Andrew Phillips, Ph.D | Independent Director | $103,794 |
| Dr. Saccomano | Director | — |
| Edward Mathers | Independent Director | $61,292 |
| Isaac Manke, Ph.D | Independent Director | $76,791 |
| Liam Ratcliffe, Ph.D | Independent Director | — |
| Michael Grey | Independent Director | $56,294 |
| R. Michael Carruthers | Independent Director | $71,294 |
| Valerie M. Jansen, M.D., Ph.D | Independent Director | $60,294 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jason Leverone, C.P.A. | OPTION | — | — | — | 65,000 | — | $304,967 |
| Samuel Agresta, M.D. | OPTION | — | — | — | 45,000 | — | 211,131 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jason Leverone, C.P.A. | $0 | $0 | $304,967 | 0.0% |
| Samuel Agresta, M.D. | 0 | 0 | 211,131 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Saccomano | Option | 495 | 13.99 | — |
| Samuel Agresta | Option | 80,298 | 18.2 | — |
| Jason Leverone | RSU | 5,105 | — | 14,805 |
| Saccomano | RSU | 1,424 | — | 4,130 |
| Samuel Agresta | Option | 34,688 | 5.19 | — |
| Saccomano | Option | 331,364 | 18.2 | — |
| Saccomano | Option | 100,209 | 5.19 | — |
| Jason Leverone | Option | 121 | 21.2 | — |
| Jason Leverone | Option | 1,774 | 13.99 | — |
| Jason Leverone | Option | 79,818 | 18.2 | — |
| Jason Leverone | Option | 50,105 | 5.19 | — |
| Samuel Agresta | Option | 10,069 | 13.99 | — |
The Board and Compensation Committee recognize the importance of base salary as a fixed source of income to attract and retain NEOs, while using annual bonuses and equity awards to align executive interests with stockholder value creation.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Andrew Phillips, Ph.DIndependent · Audit · Compensation (Chair) · Nominating and Corporate Governance (Chair) | $87,500 | $0 | $16,294 | — | $0 | $103,794 |
| Isaac Manke, Ph.DIndependent | 60,497 | 0 | 16,294 | — | 0 | 76,791 |
| R. Michael CarruthersIndependent · Audit (Chair) | 55,000 | 0 | 16,294 | — | 0 | 71,294 |
| Edward MathersIndependent · Audit · Compensation | 44,998 | 0 | 16,294 | — | 0 | 61,292 |
| Valerie M. Jansen, M.D., Ph.DIndependent · Nominating and Corporate Governance | 44,000 | 0 | 16,294 | — | 0 | 60,294 |
| Michael GreyIndependent | 40,000 | 0 | 16,294 | — | 0 | 56,294 |
| Nicholas SaccomanoEmployee director | — | — | — | — | — | 0 |
| Liam Ratcliffe, Ph.DIndependent · Newly elected | 0 | 0 | 0 | — | — | 0 |
| Dr. SaccomanoEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 5,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $331,995 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $331,995 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | OnKure Therapeutics, Inc. | 2025 | Nicholas Saccomano | $600,000 | $0 | $609,934 | $247,500 | $1,467,934 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Nicholas Saccomano | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Executive Compensation”. As printed: 1,467,934. View filing ↗ |
| 2 | Section 01, Jason Leverone | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Executive Compensation”. As printed: 896,167. View filing ↗ |
| 3 | Section 01, Samuel Agresta | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Executive Compensation”. As printed: 851,731. View filing ↗ |
| 4 | Section 03, Jason Leverone, C.P.A. OPTION | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Executive Compensation” · grants of plan-based awards table. View filing ↗ |
| 5 | Section 03, Samuel Agresta, M.D. OPTION | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Executive Compensation” · grants of plan-based awards table. View filing ↗ |
| 6 | Section 08, Andrew Phillips, Ph.D | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Director Compensation”. As printed: 103,794. View filing ↗ |
| 7 | Section 08, Isaac Manke, Ph.D | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Director Compensation”. As printed: 76,791. View filing ↗ |
| 8 | Section 08, R. Michael Carruthers | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Director Compensation”. As printed: 71,294. View filing ↗ |
| 9 | Section 08, Edward Mathers | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Director Compensation”. As printed: 61,292. View filing ↗ |
| 10 | Section 08, Valerie M. Jansen, M.D., Ph.D | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Director Compensation”. As printed: 60,294. View filing ↗ |
| 11 | Section 08, Michael Grey | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Director Compensation”. As printed: 56,294. View filing ↗ |
| 12 | Section 08, Nicholas Saccomano | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Director Compensation”. As printed: 0. View filing ↗ |
| 13 | Section 08, Liam Ratcliffe, Ph.D | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Director Compensation”. As printed: 0. View filing ↗ |
| 14 | Section 08, Dr. Saccomano | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Director Compensation”. As printed: 0. View filing ↗ |
| 15 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer. |
| 16 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options). |
| 17 | Section 09b board cost (computed) | Computed | — | — | Cash 331,995 + equity 0 + all other 0 = 331,995, summed across the director compensation table rows. |
| 18 | OnKure Therapeutics, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-21 | 0001140361-26-015903 | CEO total compensation as printed in OnKure Therapeutics, Inc.'s own proxy. As printed: 1,467,934. View filing ↗ |